Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | TAS2R38 | P59533 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 6/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.44 |
| ▸ | PHGDH | O43175 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9435834 | 0.81 | KDM4E (0.46) | CA9ALDH1A1GAANPC1RAB9A | |
| SCHEMBL9811856 | 0.81 | CA12 (0.53) | CA12CYP3A4GAANPC1RAB9A | |
| SCHEMBL9811859 | 0.81 | CA12 (0.53) | CA9CA12ALDH1A1GAANPC1 | |
| SCHEMBL9811848 | 0.80 | SMN1; SMN2 (0.50) | CA9CA12ALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL9811845 | 0.80 | MEN1 (0.53) | ALDH1A1GAANPC1RAB9AKMT2A | |
| SCHEMBL9811864 | 0.79 | ALDH1A1 (0.50) | ALDH1A1HSD17B10TP53TSHRRAB9A | |
| SCHEMBL9811910 | 0.78 | POLB (0.55) | CA9CA12ALDH1A1HSD17B10GAA | |
| SCHEMBL9811871 | 0.78 | IDO1 (0.50) | ALDH1A1GAATP53NPC1RAB9A | |
| SCHEMBL9811870 | 0.78 | CA12 (0.57) | CA12NPC1RAB9AEPHX2 | |
| SCHEMBL9811865 | 0.76 | KDM4E (0.48) | CA9CA12ALDH1A1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207565-A1 | USE OF BISPHOSPHONATES FOR PAIN TREATMENT | NOVARTIS PHARMACEUTICALS CORPORATION | 2008-08-28 | — | — | US | claimed |
| US-20060166937-A1 | Bisphosphonates for the treatment of atherosclerosis and device comprising them | PRESCOTT MARGARET F | 2006-07-27 | — | — | US | claimed |
| JP-2006504749-A | — | — | 2006-02-09 | — | — | JP | claimed |
| EP-1591122-A1 | Method of administering bisphosphonates | Novartis AG (CH) | 2005-11-02 | — | — | EP | claimed |
| EP-1178810-B8 | USE OF BISPHOSPHONIC ACIDS FOR TREATING ANGIOGENESIS | NOVARTIS AG (CH) | 2005-07-27 | — | — | EP | claimed |
| EP-1553957-A1 | BISPHOSPHONATES FOR THE TREATMENT OF ATHEROSCLEROSIS AND DEVICES COMPRISING THEM | Novartis AG (CH) | 2005-07-20 | — | — | EP | claimed |
| EP-1178810-B1 | USE OF BISPHOSPHONIC ACIDS FOR TREATING ANGIOGENESIS | NOVARTIS AG (CH) | 2005-04-20 | — | — | EP | claimed |
| EP-0854724-B1 | METHOD OF TREATING THE NAVICULAR DISEASE IN HORSES | NOVARTIS AG (CH) | 2005-03-16 | — | — | EP | claimed |
| US-20040176327-A1 | Use of bisphosphonic acids for treating angiogenesis | NOVARTIS AG (CH) | 2004-09-09 | — | — | US | claimed |
| US-20040157799-A1 | Pharmaceutical uses of bisphosphonates | SEAMAN JOHN J (US) | 2004-08-12 | — | — | US | claimed |
| US-6057306-A | ADMINISTERING BISPHOSPHONATES TO TREAT BONE DISEASE | NOVARTIS CORPORATION (US) | 2000-05-02 | — | — | US | claimed |
| US-5965547-A | INHIBITING BONE RESORPTION, USE FOR JOINT REPLACEMENT, ESPECIALLY HIP REPLACEMENT IN MAN | NOVARTIS CORPORATION (US) | 1999-10-12 | — | — | US | claimed |
| EP-0854724-A1 | METHOD OF TREATING THE NAVICULAR DISEASE IN HORSES | Novartis AG (CH) | 1998-07-29 | — | — | EP | claimed |
| WO-1997012619-A1 | METHOD OF TREATING THE NAVICULAR DISEASE IN HORSES | NOVARTIS AG (CH) | 1997-04-10 | — | — | WO | claimed |
| EP-0758241-A1 | USE OF CERTAIN METHANEBISPHOSPHONIC ACID DERIVATIVES TO PREVENT PROSTHESIS LOOSENING AND PROSTHESIS MIGRATION | Novartis AG (CH) | 1997-02-19 | — | — | EP | claimed |
| WO-1995030421-A1 | USE OF CERTAIN METHANEBISPHOSPHONIC ACID DERIVATIVES TO PREVENT PROSTHESIS LOOSENING AND PROSTHESIS MIGRATION | CIBA-GEIGY AG (CH) | 1995-11-16 | — | — | WO | claimed |
| EP-0600834-A1 | Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | claimed |
| EP-0243173-B1 | NEW DIPHOSPHONIC ACID COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-06-26 | — | — | EP | claimed |
| US-4857513-A | Diphosphonic acid compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISIWA PHARMACEUTICAL CO., LTD. (JP) | 1989-08-15 | — | — | US | claimed |
| EP-0243173-A2 | New diphosphonic acid compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-10-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207565-A1 | USE OF BISPHOSPHONATES FOR PAIN TREATMENT | SOST, OPRL1, BPGM | CA9 248/4885CA12 1036/4885ALDH1A1 2220/4885 |
| US-20060166937-A1 | Bisphosphonates for the treatment of atherosclerosis and device comprising them | SOST, PTH1R, CASR | CA9 238/4885CA12 371/4885ALDH1A1 3839/4885 |
| US-20040157799-A1 | Pharmaceutical uses of bisphosphonates | ACP3, SOST, BPGM | CA9 29/4885CA12 90/4885ALDH1A1 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.